MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-14-2026
AstraZeneca PLC Retained Earnings 2011-2026 | AZN
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings AstraZeneca PLC
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 5.3 B | 2.81 B | 5.68 B | 8.22 B | 8.14 B | 11.8 B | 13 B | 17 B | 18 B | 17.9 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18 B | 2.81 B | 10.8 B |
Quarterly Retained Earnings AstraZeneca PLC
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 1.71 B | - | 5.34 B | - | 5.3 B | - | 1.91 B | - | 2.81 B | - | 3.26 B | - | 5.68 B | - | 5.88 B | - | 8.22 B | - | 6.93 B | - | 8.14 B | - | - | - | 11.8 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.8 B | 1.71 B | 5.59 B |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M |  USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.68 | 2.44 % | $ 429 M |  Britain |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M |  Canada |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Kamada Ltd.
KMDA
|
-43.9 M | $ 8.81 | 1.73 % | $ 260 M |  Israel |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Adagene
ADAG
|
-311 M | $ 3.26 | 0.62 % | $ 183 M | China |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.28 | -2.62 % | $ 7.89 B |  Australia |
 |
Evogene Ltd.
EVGN
|
-179 M | $ 0.81 | -9.28 % | $ 27.9 M | Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Nymox Pharmaceutical Corporation
NYMX
|
-193 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.79 | -1.29 % | $ 4.31 M | China |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
-155 M | $ 0.88 | -1.43 % | $ 442 M | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Aptose Biosciences
APTO
|
-541 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-611 M | $ 224.42 | -2.52 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-2.12 B | - | -6.81 % | $ 3.04 B | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
AVROBIO
AVRO
|
-477 M | - | 1083.1 % | $ 745 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-382 M | $ 4.13 | 0.12 % | $ 352 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.36 | 2.27 % | $ 14.8 M | USA |
 |
Aptinyx
APTX
|
-353 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
-196 M | - | 17.91 % | $ 11.1 M | USA |
 |
Brickell Biotech
BBI
|
-172 M | - | -5.38 % | $ 6.06 M | USA |
 |
Codexis
CDXS
|
-563 M | $ 1.17 | -0.85 % | $ 85.9 M | USA |
 |
Athira Pharma
ATHA
|
-406 M | - | - | $ 269 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 110.12 | -0.28 % | $ 27.2 B | Germany |
 |
Amneal Pharmaceuticals
AMRX
|
-607 M | $ 14.49 | -0.75 % | $ 4.48 B | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |